| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
106,589 |
72,981 |
$4.77M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
100,724 |
60,231 |
$3.77M |
| H0020 |
Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) |
20,529 |
5,681 |
$2.13M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
14,733 |
11,198 |
$839K |
| 90837 |
Psychotherapy, 53 minutes with patient |
5,522 |
3,276 |
$444K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
3,538 |
2,713 |
$435K |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
23,940 |
13,568 |
$385K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
7,750 |
5,538 |
$262K |
| T2023 |
Targeted case management; per month |
907 |
763 |
$255K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
3,467 |
2,860 |
$188K |
| 80050 |
General health panel |
4,053 |
3,413 |
$157K |
| 80365 |
|
9,356 |
6,430 |
$117K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
6,989 |
5,767 |
$108K |
| 80373 |
|
9,336 |
6,412 |
$98K |
| 83992 |
|
9,335 |
6,411 |
$81K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,873 |
1,291 |
$63K |
| 80346 |
|
10,020 |
6,882 |
$60K |
| H0016 |
Alcohol and/or drug services; medical/somatic (medical intervention in ambulatory setting) |
321 |
310 |
$60K |
| 80369 |
|
9,337 |
6,413 |
$57K |
| 80350 |
|
9,360 |
6,427 |
$57K |
| 80348 |
|
9,599 |
6,559 |
$57K |
| 80354 |
|
9,335 |
6,410 |
$56K |
| 90834 |
Psychotherapy, 45 minutes with patient |
1,127 |
778 |
$55K |
| 82607 |
|
6,709 |
5,618 |
$53K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
323 |
228 |
$51K |
| 80061 |
Lipid panel |
7,469 |
6,115 |
$51K |
| 80358 |
|
10,014 |
6,878 |
$50K |
| 80355 |
|
9,438 |
6,490 |
$50K |
| 82746 |
|
6,406 |
5,351 |
$49K |
| 84480 |
|
7,081 |
5,902 |
$49K |
| 81003 |
|
48,098 |
31,635 |
$48K |
| 80361 |
|
9,555 |
6,587 |
$47K |
| 80372 |
|
9,336 |
6,412 |
$47K |
| 80333 |
|
9,335 |
6,411 |
$46K |
| 80337 |
|
9,336 |
6,412 |
$46K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
2,848 |
2,152 |
$43K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
7,701 |
6,324 |
$42K |
| 80368 |
|
9,335 |
6,412 |
$42K |
| 80359 |
|
9,334 |
6,411 |
$41K |
| 80356 |
|
10,007 |
6,877 |
$41K |
| 80363 |
|
9,392 |
6,455 |
$41K |
| 80324 |
|
9,549 |
6,571 |
$40K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
597 |
518 |
$39K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,621 |
1,348 |
$38K |
| 80345 |
|
9,336 |
6,412 |
$34K |
| 86769 |
|
1,149 |
968 |
$34K |
| 80366 |
|
9,335 |
6,412 |
$32K |
| 84439 |
|
7,054 |
5,890 |
$32K |
| 80349 |
|
9,560 |
6,578 |
$32K |
| H0038 |
Self-help/peer services, per 15 minutes |
1,480 |
1,119 |
$32K |
| 80353 |
|
9,336 |
6,412 |
$28K |
| 80360 |
|
9,335 |
6,411 |
$28K |
| 80323 |
|
9,325 |
6,416 |
$28K |
| 80371 |
|
9,335 |
6,412 |
$28K |
| 84403 |
|
2,260 |
1,909 |
$27K |
| H0032 |
Mental health service plan development by non-physician |
500 |
433 |
$25K |
| 80074 |
|
836 |
705 |
$25K |
| H0001 |
Alcohol and/or drug assessment |
321 |
310 |
$24K |
| 83735 |
|
6,296 |
5,252 |
$22K |
| 96127 |
|
9,221 |
6,405 |
$22K |
| 83540 |
|
6,422 |
5,289 |
$22K |
| 90791 |
Psychiatric diagnostic evaluation |
182 |
171 |
$19K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
525 |
340 |
$19K |
| 90838 |
|
243 |
149 |
$14K |
| 84550 |
|
6,110 |
5,116 |
$14K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
355 |
286 |
$13K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
679 |
593 |
$11K |
| 99215 |
Prolong outpt/office vis |
68 |
24 |
$11K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,417 |
1,046 |
$11K |
| 99417 |
Prolong home eval add 15m |
68 |
24 |
$10K |
| 86696 |
|
659 |
560 |
$8K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
57 |
31 |
$8K |
| 86645 |
|
676 |
574 |
$7K |
| 90832 |
Psychotherapy, 30 minutes with patient |
185 |
127 |
$7K |
| 86644 |
|
676 |
575 |
$6K |
| 80305 |
|
661 |
558 |
$6K |
| 80053 |
Comprehensive metabolic panel |
1,809 |
1,481 |
$6K |
| 90792 |
Psychiatric diagnostic evaluation with medical services |
54 |
50 |
$6K |
| 86695 |
|
658 |
559 |
$6K |
| 00630 |
|
110 |
78 |
$5K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
2,022 |
1,624 |
$5K |
| 87631 |
|
139 |
90 |
$5K |
| 99406 |
|
455 |
358 |
$5K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,174 |
979 |
$4K |
| 82570 |
|
789 |
537 |
$2K |
| 82728 |
|
343 |
279 |
$2K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
15 |
15 |
$2K |
| 84466 |
|
293 |
248 |
$2K |
| 86592 |
|
677 |
567 |
$2K |
| 64493 |
|
22 |
13 |
$2K |
| 99205 |
Prolong outpt/office vis |
70 |
50 |
$2K |
| 99490 |
Ccm add 20min |
602 |
528 |
$1K |
| 80367 |
|
1,984 |
1,364 |
$1K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
362 |
237 |
$1K |
| 90632 |
|
51 |
30 |
$1K |
| G0444 |
Annual depression screening, 5 to 15 minutes |
243 |
182 |
$1K |
| 64494 |
|
22 |
13 |
$919.77 |
| 81002 |
|
1,131 |
677 |
$911.42 |
| H0002 |
Behavioral health screening to determine eligibility for admission to treatment program |
20 |
17 |
$886.78 |
| G0442 |
Annual alcohol misuse screening, 5 to 15 minutes |
239 |
178 |
$849.98 |
| 86580 |
|
253 |
150 |
$840.58 |
| 36415 |
Collection of venous blood by venipuncture |
721 |
510 |
$665.49 |
| 99050 |
|
1,245 |
868 |
$646.68 |
| 71046 |
Radiologic examination, chest; 2 views |
37 |
29 |
$592.19 |
| 82947 |
|
319 |
225 |
$589.40 |
| 90674 |
|
18 |
18 |
$497.26 |
| 72100 |
|
40 |
35 |
$471.11 |
| 99072 |
|
13,945 |
9,076 |
$459.48 |
| G2067 |
Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program) |
304 |
106 |
$394.64 |
| 99348 |
|
15 |
13 |
$323.90 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
72 |
52 |
$270.50 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
47 |
42 |
$204.81 |
| 84479 |
|
143 |
104 |
$97.97 |
| 90682 |
|
16 |
15 |
$89.75 |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
17 |
13 |
$68.00 |
| 82962 |
|
51 |
39 |
$57.06 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
12 |
12 |
$45.20 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
45 |
38 |
$41.94 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
62 |
54 |
$40.09 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
155 |
113 |
$23.29 |
| 86141 |
|
43 |
26 |
$11.99 |
| J2704 |
Injection, propofol, 10 mg |
16 |
12 |
$1.40 |
| 3008F |
|
10,492 |
8,510 |
$0.10 |
| 1125F |
|
602 |
374 |
$0.01 |
| 3075F |
|
455 |
409 |
$0.00 |
| 3079F |
|
1,221 |
1,044 |
$0.00 |
| 3074F |
|
563 |
488 |
$0.00 |
| 3080F |
|
186 |
171 |
$0.00 |
| 3077F |
|
558 |
491 |
$0.00 |
| 1159F |
|
340 |
310 |
$0.00 |
| 3078F |
|
418 |
375 |
$0.00 |
| 888888 |
|
56 |
51 |
$0.00 |
| H0050 |
Alcohol and/or drug services, brief intervention, per 15 minutes |
213 |
190 |
$0.00 |
| 90785 |
|
33 |
25 |
$0.00 |
| 82977 |
|
26 |
12 |
$0.00 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
62 |
30 |
$0.00 |